The Next Generation Antibody Therapeutics Market To Upscale Through Digitized Medical Devices, Reaching US$ 6,761.1 Mn

New York, United States, 2022-Jun-03 — /EPR Network/ —

The global Next Generation Antibody Therapeutics Market is expected to witness a CAGR of 13.0% and reach US$ 6,761.1 Mn by the year 2015-2022. With how healthcare data gets accumulated these days (which could be inclusive of medical IoT solutions, DICOM files, and patient records), ultra-modern platforms like data fabrics are in the offing, so that distributed and structured data could be well-managed. This would be the healthcare industry’s situation in the upcoming period.

According to a new market report published by Persistence Market Research “Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022”, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3713

Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity. Next-generation antibody-based therapeutics enhances existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases.

Company Profiles:

• F. Hoffmann-La Roche Ltd.
• Kyowa Hakko Kirin Co., Ltd.
• Seattle Genetics, Inc.
• ImmunoGen, Inc.
• Amgen, Inc.
• Biogen.
• Bayer AG.
• Xencor, Inc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/3713

Globally, the next-generation antibody therapeutics market is witnessing significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases. In addition, rising healthcare expenditure and growing R & D activities are driving the growth of the next-generation antibody therapeutics market. However, stringent regulatory requirements and long approval time for new drug restrains the growth of the market. Similarly, high costs of next-generation antibody therapeutics is a major concern for the market.

North America is the largest market for next-generation antibody therapeutics. This is mainly due to increasing prevalence of chronic diseases and increasing healthcare spending in the region. The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. On the basis of technology, biosimilar antibody products are the fastest growing segment. On the basis of therapeutic application, oncology is the largest segment in next-generation antibody therapeutics market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/3713

The next-generation antibody therapeutics market is segmented as follows:

By Technology

• Antibody-Drug Conjugates (ADCs)
• Bispecific Antibodies (BsAbs)
• Fc Engineered Antibodies
• Antibody Fragments and Antibody-like Proteins
• Biosimilar Antibody Products

By Therapeutic Application

• Oncology
• Autoimmune/Inflammatory Diseases

By Geography

• North America
• Europe
• Asia
• Rest of the World (RoW)

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com